Meriofert Kit

Follicle-Stimulating Hormone and Luteinising Hormone, the active ingredient in Meriofert Kit, is a gonadotropin presented as a sterile injectable solution for subcutaneous use. It is employed to stimulate ovarian follicular development, estrogen production and ovulation in women with infertility related to anovulation.

GNH USA supplies Meriofert Kit as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meriofert Kit, containing FSH and LH, is used in reproductive medicine to support ovarian function.

- Infertility due to anovulation: promotes follicle growth and ovulation to improve chances of conception. - Assisted reproductive technology (ART): enhances ovarian response during IVF or ICSI cycles. - Induction of ovulation: initiates ovulation in patients with hormonal insufficiency.

Adverse reactions may occur with any gonadotropin therapy.

Common Side Effects: - Injection site pain or erythema: mild discomfort at the injection site. - Abdominal discomfort: transient bloating or cramping. - Headache: mild to moderate intensity. - Nausea: occasional upset stomach. - Breast tenderness: mild swelling or soreness. - Mild ovarian hyperstimulation: modest increase in ovarian size.

Serious or Rare Side Effects: - Severe ovarian hyperstimulation syndrome: rapid weight gain, ascites, or respiratory distress. - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Allergic reactions: rash, urticaria, or anaphylaxis. - Multiple pregnancy: twins or higher-order gestations. - Ectopic pregnancy: implantation outside the uterus. - Severe abdominal pain: possible ovarian torsion or rupture.

Before initiating therapy, clinicians should evaluate patient suitability and monitor response.

- Assess ovarian reserve: perform ultrasound and hormonal testing. - Monitor estradiol levels: check serum concentrations during stimulation. - Avoid in uncontrolled thyroid disease: correct thyroid dysfunction first. - Use caution with ovarian cysts: assess size and nature before treatment. - Contraindicated in pregnancy: do not administer to pregnant women. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions should be reviewed prior to prescribing.

Major Interactions (Avoid): - Concurrent hCG administration: may markedly increase risk of severe ovarian hyperstimulation. - High‑dose estrogen therapy: can alter gonadotropin response and increase thrombotic risk. - Combination with other gonadotropins: may cause excessive ovarian stimulation.

Moderate Interactions (Monitor Closely): - Corticosteroids: may affect hormone metabolism and response. - Thyroid hormone replacement: monitor thyroid function tests. - Antihypertensive agents: watch for blood pressure fluctuations. - Anticoagulants: increased bleeding risk if invasive procedures are performed. - NSAIDs: may mask signs of ovarian hyperstimulation.